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Prophylactic Effect of Erythropoietin Injection to Prevent Acute 
Mountain Sickness: An Open-Label Randomized Controlled 
Trial
This study was performed to evaluate whether increasing hemoglobin before ascent by 
prophylactic erythropoietin injections prevents acute mountain sickness (AMS). This open-
label, randomized, controlled trial involved 39 healthy volunteers with hemoglobin ≤15.5 
g/dL who were divided randomly into erythropoietin (n = 20) and control (n = 19) groups. 
Epoetin alpha 10,000 IU injections were given weekly for four consecutive weeks. On day 
1, and 7 days after the last injection (day 29), oxygen saturation (SaO2), and hemoglobin 
were measured. The subjects departed Seoul on day 30 and arrived at Annapurna base 
camp (ABC, 4,130 m) on day 34. AMS was diagnosed when headache and Lake Louise 
score (LLS) of ≥ 3 were present. Immediate descent criteria followed US Army 
recommendations. Two groups differ in hemoglobin levels on day 29 (15.4 ± 1.1 vs 
14.2 ± 1.0 g/dL, P = 0.001). At ABC, erythropoietin group had a significantly lower mean 
LLS, AMS incidence, and number of subjects who met immediate descent criteria. Multiple 
logistic regression analysis showed that SaO2 < 87% and control group, but not 
hemoglobin < 15.0 g/dL, independently predicted satisfaction of immediate descent 
criteria. Erythropoietin-related adverse effects were not observed. In conclusion, 
erythropoietin may be an effective prophylaxis for AMS.(Clinical Trial Registry Number; 
NCT 01665781).
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INTRODUCTION
Acute mountain sickness (AMS) is characterized by headache 
in an unacclimatized person who recently arrived at an altitude 
above 2,500 m, plus one or more of the following: gastrointesti-
nal symptoms, weakness, dizziness or lightheadedness, and 
difficulty sleeping (1, 2). Altitude acclimatization is associated 
with hypoxia-induced erythropoietin (EPO) secretion that be-
gins 1-2 days after the ascent commences, however, it takes 
weeks to affect an increase in hemoglobin (Hb) (3). EPO is a 
glycoprotein which stimulates red blood cell production. Ac-
cording to the review article about effects of recombinant hu-
man EPO in normal humans, EPO increases the arterial O2 
content not only by a increase in red blood cell volume, but also 
by a decrease in plasma volume. EPO also increases exercise 
performance and cognitive function in healthy adults (4). Sev-
eral reports have suggested that EPO may also have noneryth-
ropoietic properties that protect the brain, spinal cord, retina, 
heart, and kidney from ischemic and other types of injury (5), 
independently of its effect on Hb (6-8). While it is possible that 
Hb-elevating EPO therapy weeks before altitude exposure can 
decrease AMS, this has not been tested. The present random-
ized controlled trial was performed to assess whether prophy-
lactic EPO injections can prevent AMS.
MATERIALS AND METHODS
This study was a open-label randomized, parallel-arm, con-
trolled trial performed in Asan Medical Center, a tertiary refer-
ral university hospital. 
Participants
Participants were excluded if they had a history of cardiovascu-
lar disease or other serious illness, uncontrolled hypertension 
(> 140/90 mmHg), were current smokers, or had a known hy-
persensitivity to mammalian cell-derived products. Subjects 
with Hb > 15.5 g/dL were also excluded so that the Hb levels af-
ter EPO therapy would be < 17 g/dL. We could not estimate the 
sample size in the design of this study, because there was no si-
milar study previously and we could not do pilot study. Initially, 
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45 subjects with Hb ≤ 15.5 g/dL volunteered to participate. How-
ever, baseline testing then revealed that six men had Hb > 15.5 
g/dL and they were excluded. The remaining 39 subjects were 
enrolled after being informed of the requirements and risks of 
this research and providing written consent. There were 16 men 
and 23 women. The mean age of the cohort was 44.5 ± 12.6 yr 
(range, 18-65 yr). All subjects lived in the Seoul area at sea level. 
Interventions
The EPO group subjects were administered 10,000 IU epoetin 
alpha (Epokine®, CJ, Seoul, Korea) subcutaneous injections with 
a pre-filled syringe once per week for 4 consecutive weeks, start-
ing 5 weeks before departure. The last injection was given 7 days 
before departure. 
 Subjects were not permitted to use any self-prescribed drugs 
that could affect AMS during the 5½-week study period. Aspi-
rin 100 mg/day (Aspirin protect®, Bayer, Leverkusen, Germany) 
was prescribed to all subjects during the study period. The 10 
subjects with < 20% transferrin saturation were given iron 80 
mg/day (Feroba®, Bukwang Pharma, Seoul, Korea). These sub-
jects comprised six (two males, four females) and four (four fe-
males) subjects in the EPO and control groups, respectively. Af-
ter arriving at the 3,230 m high lodge at Deurali on day 33 of the 
study (see below), all subjects were given sildenafil citrate (Her-
agra®, CJ, Seoul, Korea) 50 mg p.o. before sleeping and on the 
following morning. This treatment was repeated when the sub-
jects arrived at the 4,130 m high lodge at Annapurna base camp 
(ABC) on day 34 (see below). Subjects who met the criteria for 
an immediate descent were treated with an intramuscular in-
jection of dexamethasone (Dexamethasone®, Yuhan, Seoul, 
Korea) 5 mg.
 The ABC is 4,130 m high and located in Nepal and was cho-
sen as the climb summit because the highest altitude in South 
Korea is 1,950 m. Moreover, many Koreans consider climbing 
to the ABC a desirable objective, which made it easy to recruit 
study participants. In total, 45 people went to the ABC, namely, 
the 39 participants, four investigators, and two research assis-
tants.
 The schedule of this study was as follows: Day 1 (24 January, 
2013): The blood pressure (BP), pulse rate (PR), arterial oxygen 
saturation (SaO2), iron status, hemoglobin (Hb), and hemato-
crit (Hct) of all subjects were measured. The first EPO injection 
was given to the EPO group. Daily aspirin (100 mg) and iron 
treatment started.
 Days 8, 15, and 22: The BP was measured and the second, 
third, and fourth EPO injections were given to the EPO group.
 Day 29: BP, PR, SaO2, iron status, Hb and Hct in all subjects 
were measured.
 Day 30: Departed from Seoul (which is at sea level) by airplane 
and arrived at Pokhara (900 m) via Kathmandu. 
 Day 31: Started trekking and arrived at Landruk (1,565 m).
 Day 32: Arrived at Sinuwa (2,360 m). 
 Day 33: Arrived at Deurali (3,230 m). Gave all subjects silde-
nafil before sleeping.
 Day 34: Gave all subjects sildenafil in the morning. Arrived at 
the ABC (4,130 m). Gave sildenafil to all subjects before sleeping.
 Day 35: Gave all subjects sildenafil in the morning. Arrived at 
Chomrong (2,170 m).
 Day 36: Arrived at Pokhara (900 m).
 Day 37: Returned to Seoul.
Outcomes
Outcomes measures were Lake Louise score (LLS), AMS inci-
dence, and number of subjects who met immediate descent cri-
teria. At 3,230 m (Deurali) and 4,130 m (ABC), each subject was 
given a LLS questionnaire that had to be completed in the eve-
ning before dinner. The LLS score is the sum of answers to five 
questions about headache, gastrointestinal symptoms (anorex-
ia, nausea, or vomiting), fatigue or weakness, dizziness or light-
headedness, and difficulty sleeping. The subjects had to rate 
these symptoms from 0 to 3, where 3 indicates severe and inca-
pacitating symptoms (1). Degree of sleep was evaluated with 
sleep last night, for example, the first LLS score at Deurali (3,230 
m) was evaluated with sleep at Sinuwa (2,360 m). If the subject 
had a headache and a total score of ≥ 3, AMS was diagnosed (1). 
Table 1 shows the immediate descent criteria by US Army Re-
search Institute of Environmental Medicine (USARIEM) (9).
 Systolic and diastolic blood pressure (SBP and DBP, respec-
tively) and pulse rate (PR) were measured by using the wrist 
blood pressure monitor BC-16 (Beuer, Ulm, Germany). Arterial 
oxygen saturation (SaO2) was measured by using a NB-Oxime-
ter (Netblue, Daegu, Korea). All measurements were performed 
2-3 hr after arrival, at rest and during breathing quietly for sev-
eral minutes before taking measurement. We measured value 
for several minutes to determine the predominant value. 
Randomization and baseline characteristics
Study subjects were randomly assigned in a 1:1 ratio to the EPO 
or control group after the baseline Hb results became available. 
The randomization sequence was generated by computer at 
Table 1. The immediate descent criteria by USARIEM*
1. High altitude cerebral edema (HACE)
   1) Mental confusion
   2) Ataxia
   3) Severe lassitude 
2. Moderate high altitude pulmonary edema (HAPE)
   1) Symptoms of dyspnea, weakness, fatigue with mild exertion; Cannot perform  
       light activities; Headache with cough, dyspnea at rest
   2) Heartbeats per min: 110-120
   3) Breaths per min: 20-30
3. LLS > 8
*Any of these items are sufficient to order an immediate descent. USARIEM, US Army 
Research Institute of Environmental Medicine; LLS, Lake Louise score.
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the Asan Medical Center. Block randomization to ensure gen-
der or age equivalence between groups was not performed.
 Twenty and nineteen subjects were randomized into the EPO 
and control groups, respectively (Table 2). Two subjects in each 
group were taking anti-hypertensive medications. 
 Comparison of the men and women in terms of baseline char-
acteristics revealed significant differences in mean Hb levels 
(14.6 ± 0.6 vs 13.3 ± 1.0 g/dL, P < 0.001), hematocrit (Hct, 42.6 ±  
1.6 vs 39.6 ± 2.5%, P < 0.001), height (171.5 ± 6.4 vs 158.0 ± 5.3 
cm, P < 0.001), weight (68.4 ± 8.0 vs 55.2 ± 6.4 kg, P < 0.001), 
SBP (129.5 ± 7.9 vs 120.1 ± 8.0 mmHg, P = 0.001), and iron sat-
uration (34.8 ± 13.2 vs 26.6 ± 10.7%, P = 0.048). However, the 
males and females did not differ in terms of age, body mass in-
dex (BMI), PR, SaO2, and DBP.
Statistical analysis
The data were presented as mean ± SD. To assess the statistical 
significance of differences between the EPO and control groups, 
Student’s t-test and Fisher’s exact test were used. Normality test 
was performed with Shapiro-Wilk test. 
 Multiple linear regression analysis was used to evaluate inde-
pendent predictors of AMS score and multiple logistic regres-
sion analysis to identify independent predictors of AMS and 
satisfaction of immediate descent criteria. To perform multi-
variate analysis, we chose dependent variables as significant 
factors for AMS score, AMS or the number of subjects who met 
immediate descent criteria in univariate analysis.
 Differences were considered to be statistically significant if P 
was < 0.05. All analyses were performed by using SPSS version 
12.0 (SPSS Inc, Evanston, IL, USA).
Ethical approval
This study was approved by the Institutional Review Board of 
the Asan Medical Center (2012-0534) and informed consent was 
given by all participants.
Trial Registration
Clinicaltrials.gov NCT01665781.
RESULTS
Five weeks after the baseline measurements on day 1 (Table 2), 
during which time the EPO group received four injections of 
EPO, the clinical parameters of the two groups were measured 
again (day 29, Table 3). The two groups did not differ in terms of 
SBP, DBP, PR, SaO2 or transferrin saturation. None of the sub-
jects started taking anti-hypertensive drugs or increased the 
dose during the 5½-week period. However, the EPO group had 
significantly higher Hb levels than the control group on day 29 
(15.4 ± 1.1 vs 14.2 ± 1.0 g/dL, P = 0.001). They also had signifi-
cantly higher percent changes in Hb relative to baseline (12.6 ±  
5.9 vs 1.4 ± 4.6%, P < 0.001). In one of the 20 EPO-treated sub-
jects, the Hb was > 17 (17.1) g/dL on day 29. Moreover, three of 
the EPO-treated subjects had Hct > 50% on day 29 (up to 50.7%). 
The males and females in the EPO group did not differ in terms 
of mean Hb increase (11.6 ± 5.7 vs 13.2 ± 6.1%, P = 0.56). In the 
EPO group, the mean EPO dose per kg of body weight was 170.8 
± 28.3 U/kg. The mean dose was significantly lower in males 
than in females (146.3 ± 17.0 vs 187.2 ± 21.7 U/kg, P < 0.001). 
This reflects the fact that the males in the EPO group had a sig-
nificantly higher body weight than the females in that group 
(69.2 ± 7.8 vs 54.2 ± 7.3 kg, P = 0.001). According to the review 
article about effects of erythropoietin in normal humans (4), the 
median weekly EPO dose in 9 studies was 162 IU/kg (range 60-
120~350 IU/kg). The mean weekly EPO dose used in this study 
was 170.8 IU/kg. 
 The two groups were then compared in terms of their clinical 
and AMS parameters at Deurali (3, 230 m) and ABC (4,130 m) 
(Table 4). The EPO group had significantly lower LLS scores at 
ABC than the control group (2.9 ± 2.7 vs 5.9 ± 3.2, P = 0.003). Of 
the whole cohort of 39 subjects, 20 (51%) developed AMS at ABC. 
Compared to the control group (74%, 14/19), significantly fewer 
EPO-treated subjects (30%, 6/20) developed AMS at ABC (P =  
0.01). The two groups did not differ in terms of SBP, DBP, PR or 
Table 2. Baseline characteristics of the study participants 
Characteristics EPO (n = 20) Control (n = 19)
Age (yr) 44.7 ± 13.0 44.3 ± 12.6
Male:female 8:12 8:11
Previous AMS history 2 0
Height (cm) 163.8 ± 7.7 163.2 ± 10.0
Weight (kg) 60.2 ± 10.5 61.1 ± 8.8
BMI (kg/m2) 22.3 ± 2.5 22.9 ± 2.2
SBP (mmHg) 123.7 ± 7.8 124.3 ± 10.6
DBP (mmHg) 76.9 ± 7.1 79.1 ± 7.9
Pulse rate (/min) 74.9 ± 8.1 72.8 ± 9.6
SaO2 (%) 98.5 ± 0.7 98.2 ± 0.9
Transferrin saturation (%) 29.7 ± 14.5 30.3 ± 10.0
Hemoglobin (g/dL) 13.7 ± 1.0 14.0 ± 1.1
Hematocrit (%) 40.5 ± 2.8 41.2 ± 2.6
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
SaO2, arterial oxygen saturation. The continuous variable data are shown as mean±SD.
Table 3. Comparison of the EPO and control groups in terms of clinical parameters 
before their departure from Seoul 
Parameters EPO (n = 20) Control (n = 19)
SBP (mmHg) 123.8 ± 11.6 122.2 ± 14.0
DBP (mmHg) 77.0 ± 7.8 79.2 ± 10.2
Pulse rate (/min) 70.2 ± 3.9 73.6 ± 9.2
SaO2 (%) 98.7 ± 0.5 98.8 ± 0.6
Transferrin saturation (%) 26.7 ± 12.3 32.6 ± 15.4
Hemoglobin (g/L)
   % change from baseline
15.4 ± 1.1*
112.6 ± 5.9*
14.2 ± 1.0
101.4 ± 4.6
Hematocrit (%)
   % change from baseline
46.0 ± 2.9*
113.7 ± 6.8* 
41.4 ± 2.5
100.7 ± 4.3
SBP, systolic blood pressure; DBP, diastolic blood pressure; SaO2, arterial oxygen sat-
uration. Values are expressed as mean±SD. *P ≤ 0.001 from control.
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SaO2. In addition, compared to the control group (53%, 10/19), 
significantly fewer EPO-treated subjects (15%, 3/20) met the 
criteria for immediate descent at 4,130 m (P = 0.019) (Table 5). 
 The 13 subjects who met the criteria for immediate descent 
had lower mean SaO2 values at ABC than the 26 subjects who 
did not (84.7 ± 4.2 vs 88.2 ± 3.4%, P = 0.017). However, the latter 
two groups did not differ in terms of SBP, DBP, hypertension, or 
PR at ABC. 
 Comparison of the 16 subjects in the whole cohort who were 
> 50 yr old to the 23 subjects who were < 50 yr old revealed 
these two groups did not differ in terms of LLS score (5.2 ± 3.6 
vs 3.7 ± 3.0, P = 0.19), AMS incidence (56% vs 43%, P = 0.75), or 
the number of subjects who met immediate descent criteria 
(50% vs 22%, P = 0.09) at ABC.
 In addition, the 16 males in the whole cohort did not differ 
from the 23 females in terms of LLS score (3.3 ± 2.5 vs 5.0 ± 3.6, 
P = 0.08), AMS incidence (38% vs 61%, P = 0.20), or the number 
of subjects who met immediate descent criteria (19% vs 43%, 
P = 0.17).
 The 23 subjects in the whole cohort whose Hb was < 15.0 g/
dL on day 29 had significantly higher LLS scores (5.8 ± 3.0 vs 
2.3 ± 2.5, P < 0.001) and AMS incidence at ABC (74% vs 19%, 
P = 0.001) than the 16 subjects whose Hb was ≥ 15.0 g/dL on 
day 29. However, these two groups did not differ in terms of the 
number of subjects who met immediate descent criteria (43% 
vs 19%, P = 0.17).
 The 16 subjects in the whole cohort whose SaO2 at ABC was 
< 87% had higher LLS scores (6.2 ± 3.5 vs 3.0 ± 2.4, P = 0.005), 
AMS incidence (75% vs 35%, P = 0.022), and number of subjects 
who met immediate descent criteria (56% vs 17%, P = 0.017) 
than the 23 subjects whose SaO2 at ABC was ≥ 87%. 
 To perform multivariate analysis, we chose three dependent 
variables, EPO group, Hb after EPO therapy and oxygen satura-
tion at ABC, which were significant factors for AMS score, AMS 
or the number of subjects who met immediate descent criteria 
in univariate analysis. Two continuous dependent variables, 
hemoglobin after EPO therapy and oxygen saturation at ABC, 
showed normal distribution.
 Multiple linear regression analysis revealed that SaO2 87% (β, 
-2.570, standard error [SE], 0.808; P = 0.003), control group (β, 
-2.237, SE, 0.833; P = 0.011), and Hb < 15.0 g/dL (β, -1.935, SE, 
0.879, P = 0.034) were independent predictors of LLS score.
 Multiple logistic regression analysis showed that Hb < 15.0 g/
dL (odds ratio [OR], 0.155; 95% confidence interval [CI], 0.027-
0.875, P = 0.035), SaO2 < 87% (OR, 0.130; 95% CI, 0.018-0.916; 
P = 0.041) and control group (OR, 0.148; 95% CI, 0.022-0.976, 
P = 0.047) were independent predictors for AMS incidence.
 Multiple logistic regression analysis also showed that SaO2 
< 87% (OR, 0.099; 95% CI, 0.015-0.659, P = 0.017) and control 
group (OR, 0.095; 95% CI, 0.012-0.719, P = 0.023), but not Hb 
< 15.0 g/dL (OR, 1.146; 95% CI, 0.177-7.429, P = 0.89), were in-
dependent predictors of the number of subjects who met the 
immediate descent criteria. During the night in ABC, one wom-
an in the control group complained of symptoms of moderate 
high altitude pulmonary edema (HAPE); headache with cough, 
dyspnea at rest. All participants returned safely and there were 
no adverse effects of EPO such as thromboembolic events.
 
DISCUSSION
To the best of our knowledge, this is the first randomized con-
trolled trial examining the ability of prophylactic EPO injections 
to prevent AMS. This study revealed that EPO pretreatment sig-
Table 4. Comparison of the EPO-treated and control groups in terms of clinical and 
AMS parameters at high altitude
Parameters EPO (n = 20) Control (n = 19)
SBP
3,230 m (Deurali)
4,130 m (ABC)
127.2 ± 12.6
133.3 ± 12.6
127.3 ± 14.9
129.7 ± 15.0
DBP
3,230 m (Deurali)
4,130 m (ABC)
81.7 ± 5.8
83.1 ± 6.4
82.3 ± 9.1
83.0 ± 9.8
Number of subjects with hypertension
3,230 m (Deurali)
4,130 m (ABC)
1
2
2
4 
Pulse rate
3,230 m (Deurali)
4,130 m (ABC)
90.1 ± 6.6
95.3 ± 11.2    
93.7 ± 8.2
101.7 ± 14.3
SaO2
3,230 m (Deurali)
4,130 m (ABC)
92.0 ± 2.7
87.2 ± 3.4
91.2 ± 3.4
86.8 ± 4.7
LLS score
3,230 m (Deurali)
4,130 m (ABC)
0.8 ± 1.4
2.9 ± 2.7*
1.4 ± 2.3
5.9 ± 3.2
Number of subjects with AMS
3,230 m (Deurali)
4,130 m (ABC)
1
  6*
  5
14
Number of subjects who met “criteria for  
   immediate descent” 
3,230 m (Deurali)
4,130 m (ABC)
0
 3†
  0
10
SBP, systolic blood pressure; DBP, diastolic blood pressure; SaO2, arterial oxygen sat-
uration; ABC, Annapurna base camp. LLS, Lake Louise score; AMS, acute mountain 
sickness. The continuous variable data are shown as mean ± SD. *P ≤ 0.01, †P <  
0.05 from control.
Table 5. Number of the participants who met the criteria for immediate descent at 
4,130 m
Criteria EPO (n = 20) Control (n = 19)
HACE (ataxia) plus HAPE (PR > 110)   1
HACE (ataxia) 1   0
HACE (severe lassitude)   1
Severe AMS plus HAPE (PR > 110) 1   1
Severe AMS alone   4
HAPE (PR > 110) 1   3
Total* 3 10
*P = 0.019. HACE, high altitude cerebral edema; HAPE, high altitude pulmonary ede-
ma; AMS, acute mountain sickness; PR, pulse rate.
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nificantly decreased LLS scores, AMS incidence, and the num-
ber of subjects who met immediate descent criteria. 
 The most likely explanation for these effects of EPO on AMS 
is that EPO pretreatment increased the Hb levels by 12.6%. Since 
the theoretical arterial oxygen content (CaO2) curve rises with 
increasing Hb until a maximum Hb of 20.7 g/dL is reached (10), 
Hb may reduce AMS by elevating CaO2 levels. 
 In this study, EPO treatment, but not Hb ≥ 15.0 g/dL, was in-
dependent predictor of the number of subjects who met imme-
diate descent criteria. While the most likely explanation for the 
effect of EPO pretreatment on AMS is that the treatment elevat-
ed Hb levels, several reports have suggested that EPO may also 
have nonerythropoietic properties that protect the brain, spinal 
cord, retina, heart, and kidney from ischemic and other types of 
injury (5). Miskowiak et al. (6, 7) reported that EPO improved 
cognitive function and memory 3 days after the administration 
in healthy volunteers; these effects occurred in the absence of 
hematological changes. Another group also reported that EPO 
reduces cerebral and systemic vascular conductance indepen-
dently of its effect on Hct in healthy male subjects (8). As an-
other example of these nonerythropoietic effects of EPO, we 
found that in dialysis patients, EPO treatment but not RBC trans-
fusion improves their muscle energy metabolism (11, 12). 
 Previous studies showed that an EPO dose of 150 IU/kg week-
ly (or 50 IU/kg three times per week) for 4 weeks increases Hb 
by 7.0%-12.0% 1-2 weeks after the last dose (13-15). In the pres-
ent study, the dose was 10,000 IU (mean 170.8 IU/kg) weekly 
for 4 weeks and 1 week after the last dose, the Hb was 12.6% 
higher relative to baseline. However, in one of the 20 EPO-treat-
ed subjects, Hb exceeded 17 g/dL, while in three subjects, Hct 
exceeded 50%. Since an excessive increase in RBC mass (Hct >  
50%) can cause possible thromboembolic events, aspirin has 
been suggested to be a preventative treatment for altitude-re-
lated thromboembolic events (9). Thromboembolic events were 
not detected in either group in this study.
 In the present study, the subjects arrived in high altitude lo-
cations ( > 2,500 m) 11 days after receiving the last dose of EPO. 
Krzyzanski et al. have shown that when healthy subjects are 
given a single dose of 20-160 kIU epoetin alpha, the RBC in-
crease peaks around 10 days (16). Thus, the RBCs of our EPO-
treated subjects may have been at their most elevated point 
when the subjects entered high altitude conditions.
 In the present study, SaO2 was another independent predic-
tor of LLS score, AMS incidence, and the number of subjects 
who met immediate descent criteria. Roach et al. (17) showed 
that SaO2 measured by noninvasive pulse oximetry correlated 
inversely with AMS severity; they also found that SaO2 may pre-
dict the development of AMS. Similarly, soldiers whose resting 
SaO2 levels are at or below the median value for a particular al-
titude are at greater risk of developing altitude sickness than in-
dividuals whose resting SaO2 exceed that median SaO2 value 
(9). Mean value of SaO2 at 4,240 m ranged 87%-87.6% (18), there-
fore, we chose 87% as a cut-off value in this study.
 In the present study, the EPO and control groups did not dif-
fer in terms of SaO2 levels at baseline, just before the departure 
from Seoul, or at high altitude. Several studies also found that 
subjects who received EPO or novel erythropoiesis stimulating 
protein (NESP) did not differ in terms of SaO2 levels from con-
trols during exercise in acute hypoxia (19, 20).
 According to a USARIEM report, when unacclimatized sol-
diers who ascend rapidly from an altitude below 1,200 m to 
4,000-4,500 m, 30%-40% develop severe AMS (9). In the present 
study, however, 58% (11/19) of the control group subjects de-
veloped severe AMS, including high altitude cerebral edema 
(HACE) and moderate HAPE. This very high rate of severe AMS 
may be due to our short acclimatization schedule. The guide-
line for acclimatization is that once one has climbed above an 
altitude of 2,500 m, the altitude at which one sleeps should not 
be increased by more than 600 m in 24 hr and an extra day of 
acclimatization should be added for every 600-1,200 m increase 
(2). In the present study, the altitude at which our subjects slept 
rose by 870 m on day 32, when the subjects climbed from Sinu-
wa (2,360 m) to Deurali (3,230 m), and by 900 m on day 33, when 
we climbed to ABC (4,130 m). The reason for this short accli-
matization schedule was that a direct flight from Seoul to Kath-
mandu was only available twice a week and most participants 
could not take 2 weeks of vacation for this study. It was decided 
that, given the beautiful sunrise over ABC, it was preferable to 
climb to ABC rather than climb to Deurali over 2 days and then 
descend (which would have met the acclimatization guidelines). 
The risks of this short acclimatization schedule were explained 
to all the participants before study and they agreed to accept 
them. 
 In this study, we employed the USARIEM guidelines for im-
mediate descent. The Lake Louise Consensus definition of HAPE 
requires that at least two symptoms (dyspnea at rest, cough, weak-
ness or decreased exercise performance, and/or chest tightness 
or congestion) and at least two signs (crackles or wheezing, cen-
tral cyanosis, tachypnea, and/or tachycardia) are met (1), while 
a diagnosis of HACE requires the onset of ataxia, altered con-
sciousness, or both in someone with AMS or HAPE (2). Howev-
er, the USARIEM recommends immediate descent when only 
moderate HAPE is observed, namely when even one or two 
symptoms or signs are present (9). Moreover, the USARIEM in-
cludes “severe lassitude” in their definition of HACE. We fol-
lowed USARIEM recommendations to ensure that we would 
detect the earlier forms of HAPE or HACE.
 Acetazolamide is widely used to prevent AMS. However, sev-
eral experts are concerned about the side effects of this drug, 
namely allergic reactions such as blood dyscrasias, Stevens-John-
son syndrome, renal failure, and toxic epidermal necrolysis (21, 
22). In the present study, all participants were given sildenafil 
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during their stay at Deurali and ABC. Sildenafil has been recom-
mended for the prevention of HAPE because of its pulmonary 
vasodilator effects (23). While the recommended preventative 
dose of sildenafil is 50 mg q 8 hr, each subject was only given 50 
mg sildenafil before sleep and in the following morning. The af-
ternoon dose was omitted because headache is the most com-
mon adverse effect of sildenafil (16% of subjects) (24), and this 
could have affected the evaluation of AMS in the evening.
 There is no US Food and Drug Administration (FDA) guide-
line of EPO use in healthy people. EPO increases the blood pres-
sure even in healthy subjects (4). However, Lundby and Olsen 
(4) concluded that EPO seems safe to use for experimental pur-
poses in healthy volunteers, because the metabolic and hor-
monal effects of EPO do not seem to range beyond physiologi-
cally acceptable limits and are reversible. EPO did not increase 
the blood pressure in this study.
 There are several limitations in our study. First, our study was 
not blinded, which may affect the results, particularly regarding 
symptoms related to AMS. Second, AMS was evaluated in the 
evening rather than in the morning, which might affect the va-
lidity of the score. We tried to identify the subjects with AMS 
and to prevent from developing severe AMS during the night. 
This reflects the fact that hypoventilation during sleep increases 
the severity of hypoxemia, which can increase AMS severity (9). 
Third, at least 10 events per variable may be needed to analyze 
by multiple logistic analysis. Only 39 participants were included 
and total 13 events of “satisfaction of immediate descent crite-
ria” happened in this study. However, this study is a exploratory 
study and this multivariate analysis is also a exploratory data 
analysis. Fourth, the numbers of subjects were relatively small 
considering diverse ages and both genders, therefore we could 
not draw a conclusion about safety of EPO in high altitude. 
 In summary, the present study shows that EPO is an effective 
prophylactic treatment for AMS in an actual mountain environ-
ment. Comparison of EPO with well-established means of pro-
phylaxis such as acetazolamide or dexamethasone needs to be 
clarified in the future study.
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